High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.

The activity and toxicity of single-agent standard-dose doxorubicin were compared with that of two schedules of high-dose epirubicin. A total of 334 chemonaive patients with histologically confirmed advanced soft-tissue sarcomas received (A) doxorubicin 75 mg m(-2) on day 1 (112 patients), (B) epiru...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, O. S., Dombernowsky, P., Mouridsen, H., Crowther, D., Verweij, J., Buesa, J., Steward, W., Daugaard, S., van Glabbeke, M., Kirkpatrick, A., Tursz, T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063236/
https://www.ncbi.nlm.nih.gov/pubmed/9862576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063236/
https://www.ncbi.nlm.nih.gov/pubmed/9862576

Ejemplares similares